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Soft-tissue sarcomas (STS) have been associated with various rare cancer syndromes and occur at increased frequencies in survivors
of childhood cancer. Also adult patients with STS have been suggested to be at an increased risk of additional malignancies. After
exclusion of syndrome-associated and radiation-induced sarcomas, we studied multiple primary malignancies in a population-based
cohort of 818 patients with primary STS of the extremities and the trunk wall. In total, 203 other malignancies developed in 164
(20%) patients median 10 (0–32) years before and median 4 (0–35) years after the sarcoma diagnosis. Standardised morbidity ratios
(SMRs) were determined for primary malignancies following a STS. Hereby individuals who had developed a STS were identified to
be at increased risk of second primary malignancies (SMR for all malignant tumours¼1.3; 95% CI¼1.0–1.5; P¼0.02) with STS being
the only specific tumour type that occurred at an increased risk (SMR¼17.6; 95% CI¼8.1–33.5; Po0.001). Hence, this population-
based series demonstrates a high frequency of second primary tumours among STS patients and indicates a particularly increased risk
of developing a new STS.
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Soft-tissue sarcomas (STS) represent less than 1% of all
malignancies and constitute a group of biologically heterogeneous
tumours. Some subtypes, for example, synovial sarcoma and
myxoid liposarcoma are characterised by specific gene fusions,
whereas others, for example, pleomorphic liposarcoma, leiomyo-
sarcoma, and undifferentiated pleomorphic sarcoma/malignant
fibrous histiocytoma (MFH) carry multiple complex genetic
alterations (Helman and Meltzer, 2003). An increased risk of STS
has been found in survivors of various types of childhood cancers,
including retinoblastoma, leukaemia, Wilms’ tumour, and Hodg-
kin’s lymphoma (Breslow et al, 1995; Beaty et al, 1995; Moll et al,
1997; Neglia et al, 2001; Bisogno et al, 2004; Fletcher et al, 2004;
Kleinerman et al, 2005). Also survivors of childhood STS,
osteosarcoma, and Ewing sarcoma have been shown to be at
increased risk of multiple primary malignancies, including bone
sarcomas and STS (Heyn et al, 1993; Pratt et al, 1997; Neglia et al,
2001; Paulussen et al, 2001; Bacci et al, 2005; Cohen et al, 2005;
Bassal et al, 2006). Development of multiple primary malignancies
may also represent a side effect of chemotherapy or radiotherapy,
which yield an increased risk of secondary malignancies, including
STS (Brady et al, 1992; Kony et al, 1997; Neglia et al, 2001;
Sheppard and Libshitz, 2001; Cormier and Pollock, 2004; Kirova
et al, 2005; Thijssens et al, 2005; Virtanen et al, 2006). Children
with STS who have been treated with radiotherapy have a nearly
eight-fold risk of developing a second malignant neoplasm,
including bone and STS (Cohen et al, 2005).
Based on current knowledge heredity, probably accounts for
only a small subset of STS, although these tumours have been
associated with several hereditary syndromes (Lynch et al, 2003).
Among these, the most well-known are neurofibromatosis due to
mutations in the NF1 gene with an increased risk for neurofibro-
sarcomas and the Li–Fraumeni syndrome caused by germline
mutations in TP53 with increased risks for STS, leukaemia, brain
tumours, and breast cancer (Lynch et al, 2003). However, STS have
been associated also with premature ageing within the Werner
syndrome and Rothmund–Thomson syndrome due to mutations
in the genes WRN and RECQ4 (Yu et al, 1996; Lindor et al,
2000) and has been described to develop in melanoma
syndrome kindreds with CDKN2A mutations and in Lynch
syndrome families with mutations in mismatch-repair genes
(Sijmons et al, 2000; Lynch et al, 2002, 2003; Medina Arana
et al, 2002; Hirata et al, 2006). In addition, STS occur in familial
forms with yet unidentified modes of inheritance and underlying
genetic causes.
Two recent studies have described development of multiple
primary malignancies in adult STS patients, and also suggested
that STS patients may be at risk of developing a second primary
STS (Merimsky et al, 2001; Tateishi et al, 2005). We used the
southern part of the Swedish Cancer Registry to identify all
individuals with STS during the time period 1964–2001 to
characterise development of multiple primary malignancies in
this cohort and to assess the risk of a second primary malignancy
after STS.
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sMATERIALS AND METHODS
The STS cohort
The National Swedish Cancer Registry is based on the Inter-
national Classification of Diseases (ICD) codes and is, because of
mandatory cancer registration by both pathologists and clinicians,
population-based and estimated to contain 99% of all malignant
diagnoses. The study is based on the southern Sweden (currently
1.7 million inhabitants) part of the registry. All individuals
diagnosed with primary STS of the extremities and trunk wall
during 1964–2001 were identified. Medical records were in all
patients scrutinised for pertinent data, that is, syndrome-
associated diseases, and previous treatment with radiotherapy
and/or chemotherapy, and all tumours have repeatedly been
reviewed by sarcoma pathologists at our tumour centre, and the
vast majority of these tumours had been reviewed by the
Scandinavian Sarcoma Review Board (Rydholm, 1983; Gustafson,
1994; Engellau, 2004). We excluded children (o16 years of age at
diagnosis), sarcomas associated with neurofibromatosis type I,
dermal sarcomas, and STS that developed in previously irradiated
fields or were associated with Stewart–Treves syndrome. Here-
after, 824 patients with primary STS of the extremities or the trunk
wall remained, but six patients who died at the time of STS
diagnosis were excluded, and the study was thus based on 818
individuals (Table 1). The histopathological reports were reviewed
to confirm primary tumour origin, location, and subtype.
Development of other primary malignancies
All other malignancies that had developed in these 818 patients
during 1958–2004 were identified in the Cancer Registry. The
histopathological reports regarding the other malignancies were
collected from 169 cases, whereas data in 34 cases relied on
information from the Cancer Registry only, most often because of
missing data at the local pathology departments. All previous
radiotherapy fields were re-evaluated regarding overlap with the
site of the secondary tumour, but only one tumour – a squamous
cell carcinoma that developed 26 years after irradiation for a
liposarcoma of the groin – was excluded since it was regarded as
radiation-induced. Soft-tissue sarcoma that developed at another
anatomical site before the development of any metastases (in the
lungs or at other sites such as lymph nodes or skeletal metastases)
were regarded as multiple primary STS, whereas STS that
developed at the same location as the primary tumour or in
patients with known metastases were regarded as local recurrences
and were thus not included in the analysis (Antonescu et al, 2000).
Furthermore, among the patients with second primary STS, five of
seven remained free of metastases after long-term follow-up.
Risk assessment
The patients within the cohort were followed from the time of STS
diagnosis to death (when they were censored) or until 31st
December 2004 when the study was closed. The cancer incidence
within the southern Swedish part of the Cancer Registry was used
as a reference. The analysis was stratified by sex, calendar year,
and 5-year age groups, that is, the cancer incidence in the STS
cohort was compared to the cancer incidence in the reference
population. The risk estimates were based only on tumours that
developed after the STS because of difficulties in compensating
for death rates from prior malignancies and after exclusion of a
squamous cell carcinoma of the skin that developed within a
previously irradiated field. Standardised morbidity ratios (SMRs)
were calculated by dividing the observed number of cancer cases
by the expected number for the total cohort (818 patients) and also
for subgroups with respect to sex, age at STS diagnosis, and with
exclusion of the 77 individuals with another primary malignancy
before the STS diagnosis. Ethical permission for the study was
granted from the Lund University ethics committee.
RESULTS
Primary tumours preceding or following the STS
Among the 818 patients, 164 (20%) developed 203 additional
primary malignancies preceding or following the STS (Table 1).
The median age at the STS diagnosis was 66 (range 16–98) years
and the median age at the first malignant diagnosis among patients
with multiple tumours, irrespective of tumour type, was 69 (31–
91) years. The other malignancies developed median 10 (0–32)
years before and median 4 (0–35) years after the sarcoma
diagnosis. One additional malignancy was found in 131
Table 1 Clinical data in whole cohort and for the 203 other malignancies in 164 patients
Second primary malignancies
Whole cohort
(n¼818)
Before sarcoma diagnosis
(n¼90)
After sarcoma diagnosis
(n¼113)
Sex (male:female) 440:378 36:41 55:41
Median age at sarcoma diagnosis (range) 66 (16–98) 74 (51–94) 69 (32–91)
Median age at diagnosis of other tumour (range) 64 (31–91) 76 (45–95)
Tumour location
a
Lower extremity 519 59 68
Upper extremity 176 25 36
Trunk wall 95 6 9
Histotypes no. (% of whole cohort) (% of subtype) (% of subtype)
MFH 306 (37) 43 (14) 50 (16)
Leiomyosarcoma 143 (17) 11 (8) 20 (14)
Synovial sarcoma 58 (7) 1 (2) 5 (10)
Liposarcoma 81 (10) 5 (6) 14 (17)
MPNST 35 (4) 8 (23) 11 (31)
Mal haemangiopericytoma 35 (4) 3 (9) 6 (17)
Other
b 160 (20) 19 (12) 7 (4)
aData missing in 28 cases.
bIncludes extraskeletal osteosarcoma, extraskeletal Ewing sarcoma, extraskeletal myxoid chondrosarcoma, soft-tissue sarcoma UNS, epitheloid
sarcoma, alveolar soft part sarcoma, angiosarcoma, clear-cell sarcoma, fibrosarcoma, haemangiosarcoma, and rhabdomyosarcoma.
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sindividuals, two additional malignancies in 27, and three
additional malignancies developed in six patients. In relation to
the type of STS, multiple primary malignancies occurred in 93 of
306 (30%) patients with MFH, in 31 of 143 (22%) patients with
leiomyosarcomas, 19 of 81 (23%) with liposarcomas, six of 58
(10%) with synovial sarcomas, 19 of 35 (54%) with malignant
peripheral nerve sheath tumours (MPNST), and in 35 of 161 (22%)
patients with STS of other subtypes.
Primary malignancies (n¼90) that developed prior to the STS
diagnosis were identified in 77 patients, nine of whom had
developed two and two of whom had developed three primary
malignancies. The most common cancer types were breast cancer
(n¼19), prostate cancer (n¼10), and malignant melanoma
(n¼10) (Table 2). Second primary malignancies (n¼113) after
the STS were identified in 96 patients. Of these, 82 patients
developed one additional malignancy, 11 developed two, and three
patients developed three additional malignancies. The second
primary malignancies developed at median age 76 (45–95) years
(Table 1). The most frequent tumour types after the STS diagnosis
were prostate cancer (n¼18) and colorectal cancer (n¼16)
(Table 2). A second STS at another anatomical location developed
in seven patients mean 4 (range 2–5) years after the primary
diagnosis, and two of these patients developed a third subsequent
STS (Table 3). Of these nine tumours, three were of another
histopathologic subtype than the primary tumour. These patients
did not have metastases at other sites and only two of seven
individuals developed subsequent lung metastases after 47 and
50 moths, respectively (Table 3). Among the 96 patients who
developed other malignancies following the STS, radiotherapy had
been administered preoperatively to one patient and postopera-
tively to 22 patients, and chemotherapy had been given
preoperatively to one patient and postoperatively to three patients.
SMR calculations
The follow-up for the whole cohort encompassed 6910 person
years and during this time 113 malignancies developed compared
to the expected number of 90, which corresponds to a SMR for
all malignancies of 1.3 (95% CI¼1.0–1.5; P¼0.02) (Table 2). The
only specific tumour type that developed at increased risk was STS
with a SMR of 17.6 (95% CI¼8.1–33.5; Po0.001) (Table 2). When
the 77 individuals with another malignancy before the STS were
excluded, similar results were obtained with a significantly
increased risk of all malignancies (SMR, all tumours¼1.3; 95%
CI¼1.0–1.5; P¼0.03) and a specifically increased risk of STS
(SMR¼17.1; 95% CI¼7.4–33.7). The increased risk of second
primary tumours was particularly high in individuals who
developed a STS after age 64 (SMR, all tumours¼1.4; 95%
CI¼1.2–1.8; Po0.01) and an increased risk of lung cancer was
identified in this subgroup (SMR¼2.2; 95% CI¼0.9–4.5;
P¼0.04).
DISCUSSION
Several causes, including treatment-related factors and heredity,
are likely to underlie development of multiple primary malig-
nancies (Kony et al, 1997). Based on data from the National
Swedish Cancer Registry, two or more primary malignancies
develop in 8–10% of all cancer patients, whereas three or more
malignancies are found in less than 1% of the patients (Swedish
board of health and welfare; http://www.sos.se/sosmenye.htm).
Centre-based studies have suggested that 7–10% of adult STS
patients develop multiple primary malignancies (before or after
the sarcoma diagnosis) (Hartley et al, 1993; Merimsky et al, 2001;
Tateishi et al, 2005). Development of a third primary tumour has
in the previous studies been reported in 1.6–2% of the patients
(Merimsky et al, 2001; Tateishi et al, 2005). In this study, one
second primary malignancy developed in 16% of the patients and
two or more other malignancies were diagnosed in 4% of the
patients, hence at higher rates than among cancer patients in
general as well as in previous reports on adult STS patients. Since
we excluded individuals with hereditary syndromes and STS within
Table 2 Second primary malignancies preceding or following the soft-
tissue sarcoma diagnosis
Tumour type
Number
observed
before
STS
Number
observed
after STS
Number
expected
after STS SMR 95% CI
All malignant tumours
a 90 113 90.2 1.3* 1.0–1.5
Prostate cancer 10 18 15.3 1.2 0.7–1.9
Colorectal cancer 5 16 12.6 1.3 0.7–2.1
Urinary tract 6 9 5.5 1.7 0.8–3.1
Lung cancer 1 9 6.4 1.4 0.7–2.7
Soft tissue 0 9 0.5 17.6** 8.1–33.5
Breast cancer 19 8 8.6 0.9 0.4–1.8
Endometrial cancer 6 5 1.8 2.8 0.9–6.4
Gastric cancer 1 5 3.6 1.4 0.5–3.2
Non-Hodgkin’s
lymphoma
5 4 2.7 1.5 0.4–3.8
Skin cancer 8 4 6.7 0.6 0.2–1.5
Pancreatic cancer 0 4 2.2 1.8 0.5–4.6
Renal cell cancer 1 3 2.2 1.4 0.3–4.0
Malignant melanoma 10 2 2.5 0.8 0.1–2.9
Hepatobiliary cancer 0 3 2.0 1.5 0.3–4.3
Chronic lymphocytic
leukaemia
2 2 0.9 2.3 0.3–8.3
Brain tumour 0 1 1.9 0.5 0.01–2.9
Thyroid gland 3 0 0.4 0.0 0.0–8.6
Ovarian cancer 3 1 1.5 0.7 0.02–3.8
CI¼confidence interval; SMR¼standardised morbidity ratio; STS¼soft-tissue
sarcoma.
aIn addition to the tumours listed below, 10 additional malignancies, for
example, head and neck cancer, developed. *P¼0.02. **Po0.001.
Table 3 Patients with multiple primary soft-tissue sarcomas
Case
no. Sex
First
STS Site Depth
Age
(years)
Second
STS Site Depth Age
Third
STS Site Depth
Age
(years)
Pulm. met.
(months)
a
1 F MFH Upper arm R D 82 MFH Buttock L D 84 MFH Scalp S 85 47
2 F MFH Shoulder R D 76 MFH Thigh L D 81 LMS Lower arm R D 85 None
3 F MFH Upper arm L S 74 MFH Lower leg R S 79 None
4 M MPNST Trunk wall S 46 AS Upper arm S 50 None
5 F MPNST Lower arm R D 59 LMS Thigh L S 63 None
6 M LS Knee L S 60 LS Axilla R D 62 None
7 M LMS Lateral thigh L S 83 LMS Medial thigh L D 87 50
AS¼angiosarcoma; D¼deep; L¼left; LMS¼leiomyosarcoma; LS¼liposarcoma; MFH¼malignant fibrous histiocytoma; MPNST¼malignant peripheral nerve sheath tumour;
R¼right; S¼superficial; STS¼soft-tissue sarcomas.
aTime from first STS to diagnosis of pulmonary metastases.
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tered to four patients, genetic and treatment-related factors are not
likely to explain the occurrence of multiple primary tumours in
our series.
The frequency of multiple primary malignancies varied between
the different STS subtypes, but may be influenced by survival
differences for the different histopathological subtypes. The lowest
rate of second malignancies was observed in patients with synovial
sarcomas (only six of 58 developed another malignancy), which is
in line with the results from Tateishi et al (2005), who did not
observe any second malignancies in individuals with synovial
sarcoma. Two previous studies have suggested that the risk of
development of multiple primary malignancies is particularly high
among STS patients with MFHs, including myxofibrosarcoma
(Merimsky et al, 2001; Tateishi et al, 2005). In our series, multiple
primary tumours most frequently occurred in patients diagnosed
with MPNST (19 of 35) followed by MFH (93 of 306) (Table 1).
Since patients with neurofibromatosis type I were excluded from
the study, the high frequency of multiple primary malignancies
in patients with MPNST is not likely to be explained by this
syndrome. Patients with neurofibromatosis type I are at a higher
risk of several tumour types, including MPNST, chronic myelo-
genous leukaemia and gliomas (Listernick et al, 1999; Korf, 2000).
However, none of these tumour types were observed among
patients diagnosed with MPNST, in whom the most common
second tumour types were breast cancer followed by prostate
cancer, STS, and tumours of the urinary tract. Merimsky et al
(2001) identified renal cell cancer and STS as the most common
second tumour types in their study of a mixed STS cohort, and
although we confirm an increased frequency of STS, we did not
find any increased risk of renal cell cancer. Tateishi et al (2005)
showed that the risk of multiple malignancies increased with the
age at diagnosis. This finding seems to be in accordance with our
study, since patients diagnosed with a STS after age 64 indicated a
larger increase compared to individuals below 65 years of age.
We analyzed the risk of multiple primary tumours in patients
previously diagnosed with STS. Overall, 113 second primary
malignancies following the sarcoma developed in 96 (12%)
patients. An increased SMR (1.3) for all malignant tumours was
found, with the only specific tumour type to develop at an
increased SMR (17.6) being a second STS. Among the seven
patients who developed a second STS, three of nine tumours were
of another histopathologic subtype and two individuals developed
three STS (Table 3). Although we required that the second STS
should be at another anatomical location and should develop
before any lung metastases, it is difficult to determine whether
multiple STS in the same individual represent multiple primary
tumours or rather an unusual pattern of metastatic disease.
Indeed, occasional cases with soft-tissue metastases from liposar-
comas, sometimes several years after the primary tumour, have
been reported (Antonescu et al, 2000), but only one of the patients
in our series presented with multiple liposarcomas. The observa-
tion of STS at different anatomical sites and with different
histopathology is in line with reports on multiple primary STS in a
small subset (0.2%) of STS patients (Antonescu et al, 2000;
Grobmyer et al, 2004).
Because of the rarity of STS, specific associations with other
cancer types may be difficult to recognise. In the context of familial
sarcoma, an association with several tumour types has been
described and besides the well-known syndromes such as
neurofibromatosis and Li–Fraumeni syndrome, STS have been
observed as a rare tumour manifestation in various other
hereditary syndromes together with, for example, melanoma,
pancreatic cancer, and colorectal cancer (Lynch et al, 2003).
Although no specific tumour type other than STS occurred at
significantly increased risk in the present study, malignant
melanoma developed in 12 patients and pancreatic cancer in four.
Development of STS has been described in association with the
CDKN2A mutation associated with the familial atypical multiple-
mole melanoma syndrome (Lynch et al, 2002, 2003). Also,
endometrial cancer occurred in 11 women and colorectal cancer
in 21 individuals, and some of these cases could signify Lynch
syndrome, since STS has been described herein (Sijmons et al,
2000; Medina Arana et al, 2002; Hirata et al, 2006). Data on family
history of cancer are not available in this material, but because of
the links of STS described to various cancer syndromes, we suggest
that a family history of cancer should be obtained in STS patients.
Specific attention should perhaps be given to cases of melanoma,
endometrial cancer, and colorectal cancer in the individual or in the
family, since these tumour types may be prevented through
screening programmes, whereas the occurrence of multiple primary
STS needs further characterisation in order to clarify its causes.
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